# SANUWAVE Health, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/SANUWAVE Health, Inc.). ## Overview SANUWAVE Health, Inc. develops and commercializes non-invasive shockwave and acoustic wave therapy systems used in wound care and other medical applications. The company is based in the United States and operates as a single-segment medical device business with sales in the U.S. and selected international markets. ## Products & services • UltraMIST® wound therapy systems • UltraMIST® disposable treatment supplies • UltraMIST® applicators and accessories • Shockwave/acoustic wave medical devices • Related service and support for installed systems - **UltraMIST® systems** (55%) — Capital equipment used to deliver non-contact wound therapy in clinical settings. - **UltraMIST® disposables** (40%) — Recurring consumables used with UltraMIST® systems during treatment sessions. - **Applicators and accessories** (3%) — Replacement parts and accessories used with the therapy platform. - **Other medical device products and services** (2%) — Smaller revenue streams from related device sales and support activities. - UltraMIST® wound therapy systems - UltraMIST® disposable treatment supplies - UltraMIST® applicators and accessories - Shockwave/acoustic wave medical devices - Related service and support for installed systems ## Customers SANUWAVE sells primarily to healthcare providers that treat chronic and acute wounds, including hospitals, outpatient wound centers, and physician practices. Its products are also used by distributors and other channel partners that place systems into clinical accounts and replenish consumables over time. Demand is tied to clinical adoption of wound therapy protocols and the installed base of UltraMIST® systems. - **Hospitals and health systems** (primary) — Buy UltraMIST® systems and consumables for inpatient and outpatient wound care programs. - **Outpatient wound care centers** (primary) — Purchase systems and disposables for recurring treatment of chronic wounds. - **Physician practices** (secondary) — Use the platform for office-based wound treatment and follow-on consumables. - **Distributors and channel partners** (secondary) — Buy and resell systems and supplies into clinical end markets. - Hospitals and health systems treating complex wounds - Outpatient wound care centers and clinics - Physician practices using wound therapy devices - Distributors and channel partners serving clinical accounts - Healthcare providers buying disposables for repeat treatments ## Geography The company generates revenue primarily in the United States, with additional sales in Europe, Canada, the Middle East, Central America, South America, Asia, and Asia/Pacific. Its significant assets and expenses are also concentrated in the United States, making the business operationally U.S.-centered even though it serves a broader international customer base. - **United States** — Management states revenues are generated primarily in the U.S. - **International** — Includes Europe, Canada, Middle East, Central America, South America, Asia, and Asia/Pacific - Revenue is generated primarily in the United States - International sales span Europe, Canada, the Middle East and Asia - Significant assets are located in the United States - Significant expenses are generated in the United States - Foreign sales add channel and regulatory complexity ## Strategy SANUWAVE’s strategy centers on expanding adoption of UltraMIST® systems while increasing recurring disposable sales from the installed base. The company also emphasizes pricing discipline, operational execution, and maintaining access to capital so it can support growth and ongoing commercialization. - **Expand UltraMIST® adoption** (medium-term) — System placements create a recurring consumables stream and deepen customer relationships. - **Grow disposable pull-through** (short-term) — Consumables drive repeat revenue after the initial system sale. - **Maintain capital flexibility** (short-term) — A medical device commercializer needs liquidity to fund operations and growth. - Grow installed base of UltraMIST® systems - Increase recurring disposable revenue per system - Maintain pricing discipline on systems and consumables - Support commercialization through operating execution - Preserve financing flexibility and capital structure ## Risks The business depends heavily on continued clinical adoption of UltraMIST® and on the company’s ability to support sales with adequate working capital. As a medical device company, it also faces regulatory, reimbursement, product liability, and competitive risks, while international sales add execution and compliance complexity. - **Dependence on UltraMIST® product line** [high] — Most revenue comes from one platform, so demand or competitive pressure on that product would affect results materially. - **Liquidity and refinancing risk** [high] — Commercialization requires ongoing capital, and debt maturities can pressure flexibility if refinancing is delayed or costly. - **Regulatory and reimbursement risk** [medium] — Medical device sales depend on approvals, clinical acceptance, and payer economics in wound care. - **Product liability and litigation** [medium] — Device companies can face claims tied to product performance, safety, or commercial disputes. - **Foreign market execution risk** [medium] — International sales require distributors, local compliance, and market-specific commercialization efforts. - Revenue concentration in UltraMIST® creates product dependence - Debt and liquidity needs can constrain operations - Medical device regulation and reimbursement can affect adoption - Product liability and litigation can create contingent exposure - International sales add channel and compliance risk ## Accounting Revenue recognition is important because the company sells both capital systems and recurring disposables, which can create different timing patterns for revenue recognition. Investors should also watch derivative accounting, stock-based compensation, debt issuance costs, and fair value changes in liabilities, all of which can materially affect reported earnings and cash flow presentation. - **Revenue recognition for systems and disposables** — Mix between capital equipment and consumables - **Derivative liabilities at fair value** — Net income and non-GAAP adjustments - **Debt issuance costs and discounts** — Non-cash financing-related expense - **Stock-based compensation** — Operating expenses and adjusted EBITDA - System sales and disposable sales may recognize revenue differently - Recurring consumables can create quarter-to-quarter mix shifts - Derivative liabilities are remeasured at fair value through earnings - Debt discounts and issuance costs affect interest and non-cash charges - Stock-based compensation adds non-cash expense to operating results --- *Last updated: 2026-04-29T04:54:32.485575+00:00*